GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Optipharm Co Ltd (XKRX:153710) » Definitions » Debt-to-Revenue

Optipharm Co (XKRX:153710) Debt-to-Revenue : 0.66 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Optipharm Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Optipharm Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩11,169 Mil. Optipharm Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩251 Mil. Optipharm Co's annualized Revenue for the quarter that ended in Mar. 2024 was ₩17,200 Mil. Optipharm Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.66.


Optipharm Co Debt-to-Revenue Historical Data

The historical data trend for Optipharm Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optipharm Co Debt-to-Revenue Chart

Optipharm Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.34 0.42 0.48 0.58

Optipharm Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.60 0.59 0.50 0.66

Competitive Comparison of Optipharm Co's Debt-to-Revenue

For the Diagnostics & Research subindustry, Optipharm Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Optipharm Co's Debt-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Optipharm Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Optipharm Co's Debt-to-Revenue falls into.



Optipharm Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Optipharm Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(9758.318 + 287.945) / 17372.568
=0.58

Optipharm Co's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(11169.239 + 250.64) / 17199.956
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Optipharm Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Optipharm Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Optipharm Co (XKRX:153710) Business Description

Traded in Other Exchanges
N/A
Address
6, 63 Osong, Hwaseong-eup, Heungduk-gu, Chungcheongbuk-do, Cheongju, KOR
Optipharm Co Ltd is engaged in developing cell therapy products through animal stem cells, developing high value-added protein drugs using bio-reactors, selecting antibiotic/antiviral components and developing products. Its diagnosis division includes human diagnosis and animal diagnosis that focuses on the development of molecular diagnostics for a variety of diseases.

Optipharm Co (XKRX:153710) Headlines

No Headlines